MDS ASH 22
Patients with MDS or AML experienced a reduction in the allele frequency of TP53 mutations in as early as cycle three.
Phillip Scheinberg, MD, talk about CHIP and the IPSS-M in MDS with Chadi Nabhan, MD, host of The HemOnc Pulse, during ASH.
Roger Lyons, MD, FACP, discusses challenges and future directions in treating patients with higher-risk MDS.
Advertisement
A recent study evaluated patients with rare myeloid neoplasms who had NPM1 mutations.
The IPSS-M Risk Stratification Model led to reclassification of almost half of patients with hypoplastic MDS.
The number of cells with chromosomal abnormalities was significantly associated with clinical features and outcomes in MDS.
Advertisement
Most patients with lower-risk MDS who had low transfusion burden before luspatercept achieved transfusion independence.
Roger Lyons, MD, FACP, discusses a real-world retrospective observational study of treatment and survival in MDS.
SX-682 was effective and well tolerated at a dose of 200 mg twice daily in patients with MDS.
A recent study evaluated the safety profile of deferiprone in patients with myelodysplastic syndromes (MDS).
A new machine-learning model based exclusively on clinical variables high prognostic accuracy for predicting MDS outcomes.
Patients with MDS or TP53-mutated acute leukemias who underwent HSCT had a one-year OS rate of 48.4%.
Venetoclax plus azacitidine maintenance after allogeneic HSCT led to a one-year OS rate of 70% in patients with AML/MDS.
More than one-third of patients with MDS and their caregivers had “concerning levels of depression and/or anxiety."
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.